Printer Friendly

Almirall gets positive test results on COPD drug.


12 January 2010 - Spain-based pharmaceutical company Almirall (MCE: ALM) and its US partner Forest Laboratories got positive preliminary results in a phase three study with their aclidinium drug for the treatment of asthma and chronic obstructive pulmonary disease (COPD), Almirall said yesterday.

The test lasted for three months and consisted of comparison between the administration of aclidinium twice a day and placebo.

According to the World Health Organisation (WHO), some 300 million people worldwide suffer from asthma while 210 million have COPD.

COPD is also known as chronic obstructive lung disease (COLD), chronic obstructive airway disease (COAD), chronic airflow limitation (CAL) and chronic obstructive respiratory disease (CORD)

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 13, 2010
Previous Article:Nutri Pharma unveils offer for vaccine developer.
Next Article:GSK to advance development of ChemoCentryx's Traficet-EN.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters